 Home > Active Ingredient News > Antitumor Therapy > JNCCN: The relationship between bone metastasis, bone-related events and survival in patients with metastatic non-small cell lung cancer (mNSCLC) treated with immune checkpoint inhibitors

JNCCN: The relationship between bone metastasis, bone-related events and survival in patients with metastatic non-small cell lung cancer (mNSCLC) treated with immune checkpoint inhibitors

 Last Update: 2021-05-20
 Source: Internet
 Author: User

Tags

reverse transcriptase inhibitors

sugar bad cancer patients

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

About more than one-third of patients with metastatic non-small cell lung cancer (m NSCLC ) have bone metastases during the course of the disease.

Recently, the Journal of The National Comprehensive Cancer Network (JNCCN) published a study to evaluate the relationship between bone metastasis, bone-related events, and survival in patients with metastatic non-small cell lung cancer treated with ICIs.

The study is a retrospective study.

Research data shows that 43 (13%) patients in the overall population have bone-related adverse events (SREs), with a median time of 2.

ICIs treatment of risk factors for bone-related events (SREs) in the overall population of mNSCLC

However, in the analysis of 124 patients with baseline bone metastases, age, gender, pathological type, mutation status, ECOG score, PDL1 and SREs were not significantly correlated.

Risk factors for bone-related events of mNSCLC with bone metastasis at baseline in ICIs treatment

Among the 124 baseline patients with bone metastases, 65 (52%) patients received BMAs treatment, but there was no significant correlation between the use of BMAs and the occurrence of SREs (P=0.

The median OS of patients with bone metastases at baseline was 5.

ICIs treatment of OS in mNSCLC patients with and without bone metastasis at baseline

In addition, 166 patients with metastatic NSCLC from the University of Michigan were analyzed as chemotherapy-only group.

OS of mNSCLC patients with and without bone metastasis at baseline accompanied by chemotherapy only

In summary, baseline bone metastasis is a poor prognostic factor for ICIs in the treatment of metastatic NSCLC, and the application of BMAs cannot prevent the occurrence of SREs and improve the prognosis of patients.
Bone metastasis at baseline is a poor prognostic factor for ICIs in the treatment of metastatic NSCLC, and the application of BMAs cannot prevent the occurrence of SREs and improve the prognosis of patients.
Bone metastasis at baseline is a poor prognostic factor for ICIs in the treatment of metastatic NSCLC, and the application of BMAs cannot prevent the occurrence of SREs and improve the prognosis of patients.

Original source:

Angel Qin, Songzhu Zhao, Abdul Miah, et al.
Bone Metastases, Skeletal-Related Events, and Survival in Patients With Metastatic Non--Small Cell Lung Cancer Treated WithImmune Checkpoint Inhibitors.
J Natl Compr Canc Netw.
2021 Apr 20;1-7 .
doi: 10.
6004/jnccn.
2020.
7668.
Online ahead of print.

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.